Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Laboratory Investigation

• Publication date

  2006-06-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/labinvest.3700444PMID 16751779
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative Aspects of Osteosarcoma

  2006cited by this paper
• p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling

  2006cited by this paper
• Macrophages: obligate partners for tumor cell migration, invasion, and metastasis.

  2006cited by this paper
• An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery

  2006cited by this paper
• Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial

  2006cited by this paper
• Absence of the p53 tumor suppressor gene promotes osteogenesis in mesenchymal stem cells.

  2006cited by this paper
• Adenovirus p53 gene therapy

  2006cited by this paper
• Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin

  2006cited by this paper
• p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress

  2006cited by this paper
• Osteoblast differentiation and skeletal development are regulated by Mdm2–p53 signaling

  2006cited by this paper
• Loss of p53 Induces Changes in the Behavior of Subventricular Zone Cells: Implication for the Genesis of Glial Tumors

  2006cited by this paper
• Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo.

  2006cited by this paper
• Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus

  2005cited by this paper
• An expression signature classifies chemotherapy-resistant pediatric osteosarcoma.

  2005cited by this paper
• The Bone-specific Expression of Runx2 Oscillates during the Cell Cycle to Support a G1-related Antiproliferative Function in Osteoblasts*

  2005cited by this paper
• Tumour stem cells and drug resistance

  2005cited by this paper
• Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes.

  2005cited by this paper
• Productive Replication of Human Adenovirus Type 5 in Canine Cells

  2005cited by this paper
• Transcription-independent pro-apoptotic functions of p53.

  2005cited by this paper
• Coxsackievirus and Adenovirus Receptor Expression on Primary Osteosarcoma Specimens and Implications for Gene Therapy with Recombinant Adenoviruses

  2005cited by this paper
• Expression of p 53 in Saos-2 Osteosarcoma Cells Induces Apoptosis Which Can Be Inhibited by BcI-2 or the Adenovirus EIB-55 kDa Protein 1

  2005cited by this paper
• The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53.

  2005cited by this paper
• p53 suppresses the self-renewal of adult neural stem cells

  2005cited by this paper
• PUMA Couples the Nuclear and Cytoplasmic Proapoptotic Function of p53

  2005cited by this paper
• Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis.

  2005cited by this paper
• CANCER-RELEVANT CULLIN-RING UBIQUITIN LIGASES

  2005cited by this paper
• Current Status of Gendicine in China: Recombinant Human Ad-p53 Agent for Treatment of Cancers

  2005cited by this paper
• p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression

  2005cited by this paper
• Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.

  2005cited by this paper
• P53 and Beta-Catenin Activity during Estrogen treatment of Osteoblasts

  2005cited by this paper
• Cell and tissue responses to genotoxic stress

  2005cited by this paper
• Stress-induced p53 runs a transcription-independent death program.

  2005cited by this paper
• A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy

  2005cited by this paper
• Gene modification strategies to induce tumor immunity.

  2005cited by this paper
• Osteosarcoma cell lines display variable individual reactions on wildtype p53 and Rb tumour‐suppressor transgenes

  2005cited by this paper
• The Interferon Regulatory Factor, IRF5, Is a Central Mediator of Toll-like Receptor 7 Signaling*

  2005cited by this paper
• The p53 pathway: positive and negative feedback loops

  2005cited by this paper
• ASPP1 and ASPP2 are new transcriptional targets of E2F

  2005cited by this paper
• Supplemental Data Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion

  2005cited by this paper
• Immortal DNA strand cosegregation requires p53/IMPDH-dependent asymmetric self-renewal associated with adult stem cells.

  2005cited by this paper
• The E2F transcriptional network: old acquaintances with new faces

  2005cited by this paper
• Reovirus sigma1 fiber incorporated into adenovirus serotype 5 enhances infectivity via a CAR-independent pathway.

  2005cited by this paper
• Probing p53 biological functions through the use of genetically engineered mouse models.

  2005cited by this paper
• Phosphorylation of Human p53 at Serine 46 Determines Promoter Selection and whether Apoptosis Is Attenuated or Amplified*

  2005cited by this paper
• Microarray analysis reveals expression regulation of Wnt antagonists in differentiating osteoblasts.

  2005cited by this paper
• Relationship of bone morphogenetic protein expression during osteoblast differentiation to wild type p53

  2005cited by this paper
• Novel link between E2F and p53: proapoptotic cofactors of p53 are transcriptionally upregulated by E2F

  2005cited by this paper
• MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation

  2005cited by this paper
• Immunosuppressive networks in the tumour environment and their therapeutic relevance

  2005cited by this paper
• Regulation of skeletal development by the Runx family of transcription factors

  2005cited by this paper
• The runx genes: gain or loss of function in cancer

  2005cited by this paper
• Complicating the complexity of p53.

  2005cited by this paper
• Conditionally replicative adenovirus expressing degradation-resistant p53 for enhanced oncolysis of human cancer cells overexpressing murine double minute 2

  2005cited by this paper
• Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model.

  2005cited by this paper
• The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis.

  2005cited by this paper
• Expression profiles of osteosarcoma that can predict response to chemotherapy.

  2005cited by this paper
• Tumor-stroma interactions.

  2005cited by this paper
• Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma

  2004cited by this paper
• Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.

  2004cited by this paper
• To die or not to die: how does p53 decide?

  2004cited by this paper
• Two Distinct Pathways of Immuno-Modulation Improve Potency of p53 Immunization in Rejecting Established Tumors

  2004cited by this paper
• Interferons, interferon‐like cytokines, and their receptors

  2004cited by this paper
• Cancer immunotherapy: moving beyond current vaccines

  2004cited by this paper
• p53-regulated Transcriptional Program Associated with Genotoxic Stress-induced Apoptosis*

  2004cited by this paper
• The three Es of cancer immunoediting.

  2004cited by this paper
• A twist code determines the onset of osteoblast differentiation.

  2004cited by this paper
• Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles.

  2004cited by this paper
• The Wnt signaling pathway in development and disease.

  2004cited by this paper
• Death in the third dimension: apoptosis regulation and tissue architecture.

  2004cited by this paper
• Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells

  2004cited by this paper
• Wnt signaling in osteoblasts and bone diseases.

  2004cited by this paper
• An adenovirus vector with a chimeric fiber derived from canine adenovirus type 2 displays novel tropism.

  2004cited by this paper
• Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis

  2004cited by this paper
• Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells.

  2004cited by this paper
• Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression

  2004cited by this paper
• Distinct roles for p53, p27Kip1, and p21Cip1 during tumor development

  2004cited by this paper
• Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.

  2004cited by this paper
• Evidence That Transfer of Functional p53 Protein Results in Increased Apoptosis in Prostate Cancer

  2004cited by this paper
• Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis.

  2004cited by this paper
• Conditionally Replicative Adenovirus with Tropism Expanded towards Integrins Inhibits Osteosarcoma Tumor Growth in Vitro and in Vivo

  2004cited by this paper
• High-Level Expression of the Coxsackievirus and Adenovirus Receptor Messenger RNA in Osteosarcoma, Ewing’s Sarcoma, and Benign Neurogenic Tumors among Musculoskeletal Tumors

  2004cited by this paper
• Review Principles of Tumor Suppression Erties of " Classic " Tumor Suppressor Genes. First, They

  2004cited by this paper
• Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells

  2004cited by this paper
• In Vitro and in Vivo Cytotoxic Activities of Recombinant Immunotoxin 8H9(Fv)-PE38 against Breast Cancer, Osteosarcoma, and Neuroblastoma

  2004cited by this paper
• A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin

  2004cited by this paper
• PTEN Regulates Mdm2 Expression through the P1 Promoter*

  2004cited by this paper
• Transductional targeting of adenoviral cancer gene therapy.

  2004cited by this paper
• Apoptosis Associated with Deregulated E2F Activity Is Dependent on E2F1 and Atm/Nbs1/Chk2

  2004cited by this paper
• E1B-55-Kilodalton Protein Is Not Required To Block p53-Induced Transcription during Adenovirus Infection

  2004cited by this paper
• The Proapoptotic Gene SIVA Is a Direct Transcriptional Target for the Tumor Suppressors p53 and E2F1*

  2004cited by this paper
• Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis

  2004cited by this paper
• Up-regulation of Bcl-2 Homology 3 (BH3)-only Proteins by E2F1 Mediates Apoptosis*

  2004cited by this paper
• Yin Yang 1 is a negative regulator of p53.

  2004cited by this paper
• Gene Therapy Progress and Prospects: cancer gene therapy using tumour suppressor genes

  2004cited by this paper
• Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion.

  2004cited by this paper
• Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

  2003cited by this paper
• Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts.

  2003cited by this paper
• PUMA mediates the apoptotic response to p53 in colorectal cancer cells

  2003cited by this paper
• mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma.

  2003cited by this paper
• Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads.

  2003cited by this paper

• Osteosarcoma: A comprehensive review of model systems and experimental therapies

  2024cites this paper
• Design of PD‐L1‐Targeted Lipid Nanoparticles to Turn on PTEN for Efficient Cancer Therapy

  2024cites this paper
• Differential p53-Mediated Cellular Responses to DNA-Damaging Therapeutic Agents

  2021cites this paper
• Studying potential PKCδ loss of function mutation and its downstream effects in gastric cancer progression

  2021cites this paper
• The research progress of Monopolar Spindle 1 Kinase (Mps1) in the treatment of tumor and osteosarcoma

  2018cites this paper
• CpG methylation patterns are associated with gene expression variation in osteosarcoma.

  2017cites this paper
• Prediction of optimal gene functions for osteosarcoma using network-based- guilt by association method based on gene oncology and microarray profile.

  2017cites this paper
• Recombinant human adenovirus-p53 improves the outcome of mid-late stage pancreatic cancer via arterial infusion.

  2017cites this paper
• Downregulation of calbindin 1, a calcium-binding protein, reduces the proliferation of osteosarcoma cells.

  2017cites this paper
• Prediction of optimal gene functions for osteosarcoma using gene ontology and microarray profiles

  2017cites this paper
• Delivery of nucleic acids for cancer gene therapy: overcoming extra- and intra-cellular barriers.

  2016cites this paper
• Effects of recombinant human adenovirus-p53 on the regression of hepatic fibrosis

  2016cites this paper
• Delivery of nucleic acids for cancer gene therapy : overcoming extra-and intracellular

  2016cites this paper
• Multifunctional Delivery Systems for Cancer Gene Therapy

  2015cites this paper
• Chapter 3 Multifunctional Delivery Systems for Cancer Gene Therapy

  2015cites this paper
• Inorganic phosphate enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin via a p53‐dependent pathway

  2013cites this paper
• Advances in adenovirus-mediated p53 cancer gene therapy

  2013cites this paper
• Inorganic phosphate as a signaling molecule: a potential strategy in osteosarcoma treatment.

  2013cites this paper
• Dual Programmed Cell Death Pathways Induced by p53 Transactivation Overcome Resistance to Oncolytic Adenovirus in Human Osteosarcoma Cells

  2013cites this paper
• E2F-1- and E2Ftr-mediated apoptosis: the role of DREAM and HRK

  2012cites this paper
• The expression and significance of IDH1 and p53 in osteosarcoma

  2010cites this paper
• Making gene therapy for osteosarcoma a reality

  2010cites this paper
• Targeted gene therapy for canine osteosarcoma : preliminary investigations

  2010cites this paper
• Molecular characterization of commonly used cell lines for bone tumor research: A trans‐European EuroBoNet effort

  2010cites this paper
• Cross‐species immunohistochemical investigation of the activation of the liver progenitor cell niche in different types of liver disease

  2009cites this paper
• Wild-type p53 in cancer cells: when a guardian turns into a blackguard.

  2009cites this paper
• Establishment of ponasterone A-inducible the wild-type p53 protein-expressing clones from HSC-1 cells, cell growth suppression by p53 expression and the suppression mechanism

  2009cites this paper
• Strategies of Gene Transfer and Silencing, and Technical Considerations

  2009cites this paper
• Targeted therapies in bone sarcomas.

  2009cites this paper
• Gene therapy for osteosarcoma: steps towards clinical studies

  2008cites this paper
• PTEN mutation: many birds with one stone in tumorigenesis.

  2008cites this paper
• Chromosome instability and tumor lethality suppression in carcinogenesis

  2008cites this paper
• P53 oncosuppressor influences selection of genomic imbalances in response to ionizing radiations in human osteosarcoma cell line SAOS-2

  2008cites this paper
• The p53 network: p53 and its downstream genes.

  2007cites this paper
• Adult human sarcomas. II. Medical oncology

  2007cites this paper
• Current Status of Gendicine in China: Recombinant Human Ad-p53 Agent for Treatment of Cancers

  2005cites this paper